# Rituximab Maintenance After Autologous Transplantation

> **NCT01103388** · PHASE3 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01103388
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-08
- **Primary completion:** 2006-04
- **Final completion:** 2010-04
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Closed early due to slow patient accrual and sponsor's withdrawal of support.
- **Last updated:** 2012-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01103388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01103388, "Rituximab Maintenance After Autologous Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01103388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*